Lyle Myers, MD
Endocrinology, Diabetes & Metabolism · Lexington, KYNPI 1255493342
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $44,693 of the $59,888 with a category attached, or 74.6%. 44 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 31.8% of the total. Reporting peaked in 2019 at $39,257 and has fallen 98.8% since, to $459 in 2025. Among endocrinology, diabetes & metabolism clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 640 payments — averaging $93.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$19K
- Boehringer Ingelheim$17K
- AstraZeneca$7K
- Lilly USA, LLC$6K
- Merck$4K
- Novo Nordisk$1K
- plus $6K from 38 others
Across 320 payments — averaging $1167.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$301K
- Sanofi US Services Inc.$73K
What the payments were for
- Consulting fees$2,9255%
- Speaking & faculty fees$44,69375%
- Travel & lodging$1,8153%
- Food & beverage$10,43217%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$21,373
- SOLIQUA 100/33$13,490
- FARXIGA$6,679
- TOUJEO$4,678
- STEGLATRO$3,640
- DISEASE STATE$119
- FreeStyle Libre$116
How this compares
$59,888 in reported general payments places this provider in the 90th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 390 | $476,943 |
| MounjaroTirzepatide | 332 | $404,131 |
| JardianceEmpagliflozin | 322 | $373,785 |
| TrulicityDulaglutide | 192 | $339,407 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 221 | $269,123 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 165 | $208,732 |
| FarxigaDapagliflozin Propanediol | 172 | $182,826 |
| Tresiba Flextouch U-200Insulin Degludec | 93 | $170,984 |
| JanuviaSitagliptin Phosphate | 145 | $158,584 |
| Tresiba Flextouch U-100Insulin Degludec | 152 | $110,557 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 94 | $97,557 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 105 | $93,157 |
| InvokanaCanagliflozin | 49 | $56,728 |
| Bydureon BciseExenatide Microspheres | 44 | $55,653 |
| Humalog Kwikpen U-100Insulin Lispro | 157 | $55,037 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $5,837 | $776,534687 claims |
| Novo NordiskOzempic, Novolog | $1,048 | $522,523518 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $16,833 | $418,237375 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $19,043 | $279,296303 claims |
| MerckJanuvia, Janumet | $3,998 | $183,216164 claims |
| AstraZenecaFarxiga | $7,497 | $182,826172 claims |
| Johnson & JohnsonInvokana | $109 | $56,72849 claims |
| Antares Pharma, Inc.Xyosted | $137 | $14,05920 claims |
| AbbVieSynthroid | $353 | $12,210194 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Lexington
- Wendell MiersLexington$38K
- Leera PatelLexington$34K
- Simon FisherLexington$26K
- Anna MarinoLexington$23K
- Gordon GuthrieLexington$14K
- Kenneth AinLexington$5K
- Megan MinchLexington$4K
- Walaa AyoubLexington$3K
- Kristina HumphriesLexington$3K
- Dennis KarounosLexington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.